Novel levamisole formulation for chronic rhinitis

A technology for chronic rhinitis and levamisole, applied in the field of levamisole nasal drops, can solve the problems of vitamin deficiency, obstacles, affecting the vasomotor and contraction of nasal mucosa, and achieve the effect of relieving inflammatory symptoms and relieving symptoms

Inactive Publication Date: 2008-01-30
JIANGSU SIMCERE PHARMACEUTICAL R & D CO LTD
4 Cites 0 Cited by

AI-Extracted Technical Summary

Problems solved by technology

[0011] (2) Vitamin deficiency, such as vitamin A or C
[0012] (3) Excessive smoking and alcohol can affect nasal mucosal vasomotor and cause obstacles
[0...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Abstract

Said invention relates to spraying agent, aerosol, atomized powder agent and nasal drop which are all made of levamisole and used for curing bull nose.

Application Domain

Technology Topic

LevamisoleChronic rhinitis +4

Examples

  • Experimental program(7)

Example Embodiment

[0053] Example 1 Levamisole spray to treat chronic rhinitis
[0054] Levamisole was used to treat 105 cases of chronic rhinitis and achieved remarkable clinical effects.
[0055] General Information There are 217 outpatient cases, including 142 males and 75 females; the age range is 16 to 44 years, with an average of 27 years. The patient's course of illness was 13 months to 12 years. There were 63 cases of chronic simple rhinitis and 154 cases of chronic hypertrophic rhinitis. All cases have received drug treatment, 11 cases have received cryotherapy, 23 cases have received laser treatment, and 17 cases have received inferior turbinate drug injection. The drug is unknown.
[0056] Treatment method Patients were randomly divided into levamisole treatment group (105 cases, including 36 cases of chronic simple rhinitis and 69 cases of chronic hypertrophic rhinitis) and control group (112 cases, including 27 cases of chronic simple rhinitis and 85 cases of chronic hypertrophic rhinitis) ). The levamisole treatment group was treated with levamisole spray, and the nasal cavity was administered twice a day at a dose of 100ug/0.14ml per spray. The control group was treated with 0.25% chloramphenicol ephedrine liquid, dripped or sprayed into the nasal cavity, 3 to 5 drops each time. The treatment course of the two groups was one week, during which other anti-inflammatory drugs and other types of nasal drops were prohibited.
[0057] Efficacy evaluation criteria are based on the inspection at the last follow-up. Healing: The symptoms of nasal congestion disappeared completely, the nasal cavity was fully ventilated, nasal secretions and sense of smell were also improved, and the inferior turbinate was significantly reduced. Improvement: The nasal congestion is significantly improved, only slight nasal congestion occurs when the upper respiratory tract infection or lying on the side, and the inferior turbinate shrinks to varying degrees from before treatment. Invalid: No improvement in nasal congestion and no change in inferior turbinate during follow-up.
[0058] Results The two groups were followed up 4 times at 1 week, 2 weeks, 1 month and 3 months after treatment, and were followed up irregularly thereafter. The longest follow-up time was 9 months, the shortest was 1 month, and the average follow-up was 4 months.
[0059] Among 105 patients in the levamisole treatment group, 36 patients had chronic simple rhinitis (29 were cured, 7 improved, 0 was ineffective, and the total effective rate was 100%); 69 patients had chronic hypertrophic rhinitis (51 cured, 13 improved) Cases, 5 cases were invalid, the total effective rate was 92.8%).
[0060] Among 112 patients in the control group with 0.25% chloramphenicol ephedrine solution, 27 cases had chronic simple rhinitis (7 cases were cured, 10 cases improved, 10 cases were ineffective, and the total effective rate was 63%); 85 cases had chronic hypertrophic rhinitis ( 2 cases were cured, 56 cases improved, 27 cases were ineffective, and the total effective rate was 68.3%).
[0061] Therefore, levamisole has a high effective rate in the treatment of chronic rhinitis, and the curative effect is higher than 0.25% chloramphenicol ephedrine solution.

Example Embodiment

[0062] Example 2 Treatment of Chronic Rhinitis with Levamisole Aerosol
[0063] Repeat the experiment described in "Example 1", except that levamisole aerosol (dose of 70ug/0.14ml per spray) was used as the therapeutic agent and the condition and number of patients observed were different, the criteria for patient admission, treatment plan, The curative effect judgment standard is the same as "Example 1", and the experimental results are similar to "Example 1", that is, levamisole aerosol is used to treat chronic rhinitis, and its curative effect is better than 0.25% chloramphenicol ephedrine solution.

Example Embodiment

[0064] Example 3 Treatment of chronic rhinitis with levamisole nose drops
[0065] Repeat the experiment described in "Example 1", except that the treatment is levamisole nasal drops (concentration 350ug/ml), the method of administration is to change each spray of the spray to each nasal drip and observe the patient’s condition Except for the difference in number, the criteria for enrollment, treatment plan, and efficacy judgment of patients are the same as in "Example 1", and the experimental results are similar to "Example 1", that is, levamisole nasal drops are used to treat chronic rhinitis, and its efficacy is better than 0.25 % Chloramphenicol ephedrine solution.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

no PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Similar technology patents

Classification and recommendation of technical efficacy words

  • Relieve symptoms
  • Relieves symptoms of inflammation

Multi fluid tissue resection methods and devices

ActiveUS20110184391A1Relieve symptomsImprove resection efficiencyEye surgeryCatheterTherapeutic AreaCarcinoma
Owner:AQUABEAM

Topical Compositions Containing Phosphorylated Polyphenols

InactiveUS20080095866A1Great of compositional integrityRelieve symptomsBiocidePhosphorous compound active ingredientsEnzymeCutaneous condition
Owner:AJINOMOTO OMNICHEM SA +1

Vaginal plug film with micrometer holes

InactiveCN106580926ARelieves symptoms of inflammationAntibacterial agentsOrganic active ingredientsAnti-inflammatoryDuctility
Owner:香港和和有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products